Noteworthy, for patients with lung adenocarcinoma a potential link between the ABCG2 expression and clinical outcome has been proposed; thus, expression of ABCG2 in combination with CD133 expression (ABCG2+/CD133+ NSCLC status) was found to be a predictor of a high risk of early relapse [41]. Here, ABCG2 is linked to lung adenocarcinoma.